Causes and Effects of Cellular Oxidative Stress as a Result of MDMA Abuse

Current Pharmaceutical Biotechnology

Volumn 11, Issue 5, 2010, Pages 444-452

  Fiaschi, Anna Ida ^a   Cerretani, Daniela ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Antioxidant enzymes; Ascorbic acid; Glutathione; Lipoperoxidation; MDMA; Oxidative stress; ROS; Toxicity

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CATECHOLAMINE; FREE RADICAL; MONOAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ARTICLE; AUTOOXIDATION; CARDIOTOXICITY; CELL DAMAGE; CELL DEATH; CELL STRESS; DEAMINATION; DRUG ABUSE; DRUG CYTOTOXICITY; HUMAN; HYPERTHERMIA; LIPID PEROXIDATION; LIVER TOXICITY; NEPHROTOXICITY; NEUROTOXICITY; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; HUMANS; MODELS, BIOLOGICAL; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; OXIDATIVE STRESS; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

ANIMALIA;

EID: 77956587980     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920110791591544     Document Type: Article

References (86)

1. Kovacic, P.; Jacintho, J.D. Reproductive toxins: pervasive theme of oxidative stress and electron transfer. Curr. Med. Chem., 2001, 8(7), 863-892.
2. Ridnour, L.A.; Thomas, D.D.; Mancardi, D.; Espey, M.G.; Miranda, K.M.; Paolocci, N.; Feelisch, M.; Fukuto, J.; Wink, D.A. The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations. Biol. Chem., 2004, 385(1), 1-10.
3. Stephans, S.E.; Yamamoto, B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse, 1994, 17(3), 203-209.
4. Raiteri, M.; Cerrito, F.; Cervoni, A.M.; Levi, G. Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J. Pharmacol. Exp. Ther., 1979, 208(2), 195-202.
5. Michel, P.P.; Hefti, F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res., 1990, 26(4), 428-435.
6. Colado, M.I.; O'Shea, E.; Granados, R.; Murray, T.K.; Green, A.R. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ("ecstasy") and p-chloroamphetamine but not the degeneration following fenfluramine. Br. J. Pharmacol., 1997, 121(5), 889-900.
7. Shankaran, M.; Yamamoto, B.K.; Gudelsky, G.A. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Synapse, 2001, 40(1), 55-64.
8. Sprague, J.E.; Nichols, D.E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther., 1995, 273(2), 667-673.
9. Wagner, G.C.; Carelli, R.M.; Jarvis, M.F. Ascorbic acid reduces the dopamine depletion induced by methamphetamine and the 1-methyl-4-phenyl pyridinium ion. Neuropharmacology, 1986, 25(5), 559-561.
10. Colado, M.I.; Green, A.R. The spin trap reagent alpha-phenyl-N-tert-butyl nitrone prevents 'ecstasy'-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur. J. Pharmacol., 1995, 280(3), 343-346.
11. Carvalho, M.; Remiao, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Carvalho, F.; Bastos, M.L. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology, 2004a, 200(2-3), 193-203.
12. Carvalho, M.; Remiao, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Monteiro, C.; Goncalves, M.J.; Seabra, V.; Amado, F.; Carvalho, F.; Bastos, M.L. Metabolism is required for the expression of ecstasy-induced cardiotoxicity in vitro. Chem. Res. Toxicol., 2004b, 17(5), 623-632.
13. Bai, F.; Lau, S.S.; Monks, T.J. Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. Chem. Res. Toxicol., 1999, 12(12), 1150-1157.
14. Cerretani, D.; Riezzo, I.; Fiaschi, A.I.; Centini, F.; Giorgi, G.; D'Errico, S.; Fiore, C.; Karch, S.B.; Neri, M.; Pomara, C.; Turillazzi, E.; Fineschi, V. Cardiac oxidative stress determination and myocardial morphology after a single ecstasy (MDMA) administration in a rat model. Int. J. Legal. Med., 2008, 122(6), 461-469.
15. Remiao, F.; Carmo, H.; Carvalho, F.D.; Bastos, M.L. Inhibition of glutathione reductase by isoproterenol oxidation products. J. Enzyme Inhib., 2000, 15(1), 47-61.
16. 2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem. Res. Toxicol., 2002, 15(6), 861-869.
17. Cleary, L.; Docherty, J.R. Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur. J. Pharmacol., 2003, 476(1-2), 31-34.
18. Tiangco, D.A.; Lattanzio, F.A. Jr.; Osgood, C.J.; Beebe, S.J.; Kerry, J.A.; Hargrave, B.Y. 3,4-Methylenedioxymethamphetamine activates nuclear factor-kappaB, increases intracellular calcium, and modulates gene transcription in rat heart cells. Cardiovasc. Toxicol., 2005, 5(3), 301-310.
19. Milei, J.; Forcada, P.; Fraga, C.G.; Grana, D.R.; Iannelli, G.; Chiariello, M.; Tritto, I.; Ambrosio, G. Relationship between oxidative stress, lipid peroxidation, and ultrastructural damage in patients with coronary artery disease undergoing cardioplegic arrest/reperfusion. Cardiovasc. Res., 2007, 73(4), 710-719.
20. Beckman, J.S.; Beckman, T.W.; Chen, J.; Marshall, P.A.; Freeman, B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA, 1990, 87(4), 1620-1624.
21. Colado, M.I.; Camarero, J.; Mechan, A.O.; Sanchez, V.; Esteban, B.; Elliot, J.M.; Green, A.R. A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on dopamine neurones in mouse brain. Br. J. Pharmacol., 2001, 134(8), 1711-1723.
22. Quinton, M.S.; Yamamoto, B.K. Causes and consequences of methamphetamine and MDMA toxicity. AAPS J., 2006, 8(2), E337-E347.
23. Kuhn, D.M.; Sadidi, M.; Liu, X.; Kreipke, C.; Geddes, T.; Borges, C.; Watson, J.T. Peroxynitrite-induced nitration of tyrosine hydroxylase: identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. J. Biol. Chem., 2002, 277(16), 14336-14342.
24. Riezzo, I.; Cerretani, D.; Fiore, C.; Bello, S.; Centini, F.; D'Errico, S.; Fiaschi, A.I.; Giorgi, G.; Neri, M.; Pomara, C.; Turillazzi, E.; Fineschi, V. Enzymatic-nonenzymatic cellular antioxidant defense systems response and immunohistochemical detection of MDMA, VMAT2, HSP70, and apoptosis as biomarkers for MDMA (Ec-stasy) neurotoxicity. J. Neurosci. Res., 2010, 88(4), 905-916.
25. Yamamoto, B.K.; Raudensky, J. The role of oxidative stress, metabolic compromise, and inflammation in neuronal injury produced by amphetamine-related drugs of abuse. J. Neuroimmune Pharmacol., 2008, 3(4), 203-217.
26. Nagatsu, T. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology, 2004, 25(1-2), 11-20.
27. Alves, E.; Summavielle, T.; Alves, C.J.; Gomes-da-Silva, J.; Barata, J.C.; Fernandes, E.; de Lourdes Bastos, M.; Tavares, M.A.; Carvalho, F. Monoamine oxidase-B mediates ecstasy-induced neurotoxic effects to adolescent rat brain mitochondria. J. Neurosci., 2007, 27(38), 10203-10210.
28. Sprague, J.E.; Nichols, D.E. Inhibition of MAO-B protects against MDMA-induced neurotoxicity in the striatum. Psychopharmacology (Berl), 1995, 118(3), 357-359.
29. Sprague, J.E.; Everman, S.L.; Nichols, D.E. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology, 1998, 19(3), 427-441.
30. Marchitti, S.A.; Deitrich, R.A.; Vasiliou, V. Neurotoxicity and metabolism of the catecholamine-derived 3,4-dihydroxy-phenylacetaldehyde and 3,4-dihydroxyphenylglycolaldehyde: the role of aldehyde dehydrogenase. Pharmacol. Rev., 2007, 59(2), 125-150.
31. Sattler, R.; Tymianski, M. Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol. Neurobiol., 2001, 24(1-3), 107-129.
32. Sattler, R.; Tymianski, M. Molecular mechanisms of calcium-dependent excitotoxicity. J. Mol. Med., 2000, 78(1), 3-13.
33. Fleckenstein, A.E.; Hanson, G.R. Impact of psychostimulants on vescicular monoamine transporter function. Eur. J. Pharmacol., 2003, 479(1-3), 283-289.
34. Rothman, R.B.; Baumann, M.H. Monoamine transporters and psychostimulant drugs. Eur. J. Pharmacol., 2003, 479(1-3), 23-40.
35. Wrona, M.Z.; Dryhurst, G. Oxidation of serotonin by superoxide radical: implications to neurodegenerative brain disorders. Chem. Res. Toxicol., 1998, 11(6), 639-650.
36. Jiang, X.R.; Dryhurst, G. Inhibition of the alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase complexes by a putative aberrant metabolite of serotonin, tryptamine-4,5-dione. Chem. Res. Toxicol., 2002, 15(10), 1242-1247.
37. Kuhn, D.M.; Arthur, R.E. Jr. L-DOPA-quinone inactivates tryptophan hydroxylase and converts the enzyme to a redox-cycling quinoprotein. Brain Res. Mol. Brain Res., 1999, 73(1-2), 78-84.
38. Kuhn, D.M.; Geddes, T.J. Peroxynitrite inactivates tryptophan hydroxylase via sulfhydryl oxidation. Coincident nitration of enzyme tyrosyl residues has minimal impact on catalytic activity. J. Biol. Chem., 1999, 274(42), 29726-29732.
39. Kuhn, D.M.; Aretha, C.W.; Geddes, T.J. Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J. Neurosci., 1999, 19(23), 10289-10294.
40. Stone, D.M.; Hanson, G.R.; Gibb, J.W. In vitro reactivation of rat cortical tryptophan hydroxylase following in vivo inactivation by methylenedioxymethamphetamine. J. Neurochem., 1989, 53(2), 572-581.
41. Kuhn, D.M.; Geddes, T.J. Molecular footprints of neurotoxic amphetamine action. Ann. N Y Acad. Sci., 2000, 914, 92-103.
42. Shankaran, M.; Yamamoto, B.K.; Gudelsky, G.A. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur. J. Pharmacol., 1999, 385(2-3), 103-110.
43. Colado, M.I.; O'Shea, E.; Esteban, B.; Granados, R.; Green, A.R. In vivo evidence against clomethiazole being neuroprotective against MDMA ("ecstasy")-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism. Neuropharmacology, 1999, 38(2), 307-314.
44. Capela, J.P.; Carmo, H.; Remião, F.; Bastos, M.L.; Meisel, A.; Carvalho, F. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol. Neurobiol., 2009, 39(3), 210-271.
45. Capela, J.P.; Ruscher, K.; Lautenschlager, M.; Freyer, D.; Dirnagl, U.; Gaio, A.R.; Bastos, M.L.; Meisel, A.; Carvalho, F. Ecstasy-induced cell death in cortical neuronal cultures is serotonin 2A-receptor-dependent and potentiated under hyperthermia. Neuroscience, 2006, 139(3), 1069-1081.
46. Capela, J.P.; Fernandes, E.; Remiao, F.; Bastos, M.L.; Meisel, A.; Carvalho, F. Ecstasy induces apoptosis via 5-HT(2A)-receptor stimulation in cortical neurons. Neurotoxicology, 2007b, 28(4), 868-875.
47. Jayanthi, S.; Ladenheim, B.; Andrews, A.M.; Cadet, J.L. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymeth-amphetamine (Ecstasy). Neuroscience, 1999, 91(4), 1379-1387.
48. Capela, J.P.; Macedo, C.; Branco, P.S.; Ferreira, L.M.; Lobo, A.M.; Fernandes, E.; Remião, F.; Bastos, M.L.; Dirnagl, U.; Meisel, A.; Carvalho, F. Neurotoxicity mechanisms of thioether ecstasy metabolites. Neuroscience, 2007a, 146(4), 1743-1757.
49. Thiriet, N.; Ladenheim, B.; McCoy, M.T.; Cadet, J.L. Analysis of ecstasy (MDMA)-induced transcriptional responses in the rat cortex. FASEB J., 2002, 16(14), 1887-1894.
50. de la Torre, R.; Farre, M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol. Sci., 2004, 25(10), 505-508.
51. Erives, G.V.; Lau, S.S.; Monks, T.J. Accumulation of neurotoxic thioether metabolites of 3,4-(+/-)-methylenedioxymetham-phetamine in rat brain. J. Pharmacol. Exp. Ther., 2008, 324(1), 284-291.
52. Yamamoto, B.K.; Zhu, W. The effects of methamphetamine on the production of free radicals and oxidative stress. J. Pharmacol. Exp. Ther., 1998, 287(1), 107-114.
53. Shankaran, M.; Yamamoto, B.K.; Gudelsky, G.A. Mazindol attenuates the 3,4-methylenedioxymethamphetamine-induced formation of hydroxyl radicals and long-term depletion of serotonin in the striatum. J. Neurochem., 1999, 72(6), 2516-2522.
54. Giovanni, A.; Liang, L.P.; Hastings, T.G.; Zigmond, M.J. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem., 1995, 64(4), 1819-1825.
55. Gluck, M.R.; Moy, L.Y.; Jayatilleke, E.; Hogan, K.A.; Manzino, L.; Sonsalla, P.K. Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem., 2001, 79(1), 152-160.
56. Farfel, G.M.; Seiden, L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther., 1995, 272(2), 868-875.
57. Malberg, J.E.; Sabol, K.E.; Seiden, L.S. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J. Pharmacol. Exp. Ther., 1996, 278(1), 258-267.
58. Jones, D.C.; Lau, S.S.; Monks, T.J. Thioether metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymetham-phetamine inhibit human serotonin transporter (hSERT) function and simultaneously stimulate dopamine uptake into hSERT-expressing SK-N-MC cells. J. Pharmacol. Exp. Ther., 2004, 311(1), 298-306.
59. Jones, A.L.; Simpson, J. Review article: mechanisms and management of hepatotoxicity in ecstasy (MDMA) and amphetamine intoxications. Aliment. Pharmacol. Ther., 1999, 13(2), 129-133.
60. Hall, A.P.; Henry, J.A. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth., 2006, 96(6), 678-685.
61. Carvalho, M.; Carvalho, F.; Remião, F.; de Lourdes Pereira, M.; Pires-das-Neves, R.; de Lourdes Bastos, M. Effect of 3,4-methylenedioxymethamphetamine (ecstasy) on body temperature and liver antioxidant status in mice: influence of ambient temperature. Arch. Toxicol., 2002, 76(3), 166-172.
62. Bolton, J.L.; Trush, M.A.; Penning, T.M.; Dryhurst, G.; Monks, T.J. Role of quinones in toxicology. Chem. Res. Toxicol., 2000, 13(3), 135-160.
63. Montiel-Duarte, C.; Ansorena, E.; Lopez-Zabalza, M.J.; Cenarruzabeitia, E.; Iraburu, M.J.; Cenarruzabeitia, E.; Iraburu, M.J. Role of reactive oxygen species, glutathione and NF-kappaB in apoptosis induced by 3,4-methylenedioxymethamphetamine ("Ecstasy") on hepatic stellate cells. Biochem. Pharmacol., 2004, 67(6), 1025-1033.
64. Bindoli, A.; Rigobello, M.P.; Deeble, D.J. Biochemical and toxicological properties of the oxidation products of catecholamines. Free Radic. Biol. Med., 1992, 13(4), 391-405.
65. Hiramatsu, M.; Kumagai, Y.; Unger, SE.; Cho, A.K. Metabolism of methylenedioxymethamphetamine: formation of dihydroxymeth-amphetamine and a quinone identified as its glutathione adduct. J. Pharmacol. Exp. Ther., 1990, 254(2), 521-527.
66. Fisher, A.A.; Labenski, M.T.; Malladi, S.; Gokhale, V.; Bowen, M.E.; Milleron, R.S.; Bratton, S.B.; Monks, T.J.; Lau, S.S. Quinone electrophiles selectively adduct electrophile binding motifs within cytochrome c. Biochemistry, 2007, 46(39), 11090-11100.
67. Carvalho, M.; Carvalho, F.; Bastos, M.L. Is hyperthermia the triggering factor for hepatotoxicity induced by 3,4-methylenedioxy-methamphetamine (ecstasy)? An in vitro study using freshly isolated mouse hepatocytes. Arch. Toxicol., 2001, 74(12), 789-793.
68. Beitia, G.; Cobreros, A.; Sainz, L.; Cenarruzabeitia, E. Ecstasy-induced toxicity in rat liver. Liver, 2000, 20(1), 8-15.
69. Carvalho, M.; Remiao, F.; Milhazes, N.; Borges, F.; Fernandes, E.; Carvalho, F.; Bastos, M.L. The toxicity of N-methyl-alpha-methyldopamine to freshly isolated rat hepatocytes is prevented by ascorbic acid and N-acetylcysteine. Toxicology, 2004, 200(2-3), 193-203.
70. Moon, K.H.; Upreti, V.V.; Yu, L.R.; Lee, I.J.; Ye, X.; Eddington, N.D.; Veenstra, T.D.; Song, B.J. Mechanism of 3,4-methyl-enedioxymethamphetamine (MDMA, ecstasy)-mediated mitochon-drial dysfunction in rat liver. Proteomics, 2008, 8(18), 3906-3918.
71. Nakagawa, Y.; Suzuki, T.; Tayama, S.; Ishii, H.; Ogata, A. Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes. Arch. Toxicol., 2009, 83(1), 69-80.
72. Henry, J.A.; Jeffreys, K.J.; Dawling, S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (ecstasy). Lancet, 1992, 340(8816), 384-387.
73. Suarez, R.; Riemersma, R. "Ecstasy" and sudden cardiac death. Am. J. Forensic Med. Pathol., 1988, 9(4), 339-341.
74. O'Cain, P.; Hletko, S.; Ogden, B.; Varner, K. Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol. Behav., 2000, 70(1-2), 141-148.
75. Lester, S.J.; Baggott, M.; Welm, S.; Schiller, N.B.; Jones, R.T.; Foster, E.; Mendelson, J. Cardiovascular effects of 3,4-methylenedioxymethamphetamine. A double-blind, placebo-controlled trial. Ann. Intern. Med., 2000, 133(12), 969-973.
76. Fitzgerald, J.L.; Reid, J.J. Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J. Pharm. Pharmacol., 1994, 46(10), 826-832.
77. Varner, K.Y.; Delcarpio, J.B.; Moerschbaecher, J.M. Cardiac toxicity elicited by repeated administration of 3,4-methyl-enedioxy-methamphetamine (MDMA). NIDA Res. Monogr., 1998, 179, 214.
78. Carvalho, M.; Hawksworth, G.; Milhazes, N.; Borges, F.; Monks, T.; Fernandes, E.; Carvalho, F.; Bastos, M. L. Role of metabolites in MDMA (ecstasy)-induced nephrotoxicity: an in vitro study using rat and human renal proximal tubular cells. Arch. Toxicol., 2002, 76(10), 581-588.
79. Kreth, K.P.; Kovar, K.A.; Schwab, M.; Zanger, U.M. Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. Biochem. Pharmacol., 2000, 59(12), 1563-1571.
80. Shenouda, S.K.; Lord, K.C.; McIlwain, E.; Lucchesi, P.A.; Varner, K.J. Ecstasy produces left ventricular dysfunction and oxidative stress in rats. Cardiovasc. Res., 2008, 79(4), 662-670.
81. Shenouda, S.K.; Varner, K.J.; Carvalho, F.; Lucchesi P.A. Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. Cardiovasc. Toxicol., 2009, 9(1), 30-38.
82. Dixon, I.M.; Kaneko, M.; Hata, T.; Panagia, V.; Dhalla, N.S. Alterations in cardiac membrane Ca2+ transport during oxidative stress. Mol. Cell. Biochem., 1990, 99(2), 125-133.
83. Dixon, I.M.; Hata, T.; Dhalla, N.S. Sarcolemmal calcium transport in congestive heart failure due to myocardial infarction in rats. Am. J. Physiol., 1992, 262(5 pt 2), H1387-1394.
84. Campbell, G.A.; Rosner, M.H. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin. J. Am. Soc. Nephrol., 2008, 3(6), 1852-1860.
85. Ninkovi, M.; Selakovi, V.; Duki, M.; Milosavljevi, P.; Vasiljevi, I.; Jovanovi, M. Malicevi, Z. Oxidative stress in rat kidneys due to 3,4-methylenedioxymetamphetamine (ecstasy) toxicity. Nephrology (Carlton), 2008, 13(1), 33-37.
86. Darvesh, A.S.; Shankaran, M.; Gudelsky, G.A. 3,4-Methyl-enedioxymethamphetamine produces glycogenolysis and increases the extracellular concentration of glucose in the rat brain. J. Pharmacol. Exp. Ther., 2002, 301(1),138-144.